A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions

Coronary Artery Disease Clinical Trial

— CREDIT  

Official title:

A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01909869
• Other study ID #: H-2012-12
• Status: Completed
• Phase: N/A
• Start date: January 2013
• Est. completion date: June 4, 2019

Study information

• Verified date: April 2023
• Source: JW Medical Systems Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One of the purpose of this study is to assess the preliminary safety and feasibility,and to provide related information and evidence for the design of the further pivotal randomized control trial.the other purpose is to assess the performace of the stent delivery system.

Description:

1. Single-center, prospective, pilot study

2. De novo,coronary artery, single vessel and single lesion

3. Sample size = 45

4. Follow- up clinical or phone at 1-month,9-month and annually 2 to 5 years

5. Randomization 2:1 Angio and OCT scheduled follow-up in the hospital

6. Follow-up Angio and OCT randomized 30 patients for 4-month and 15 patiens for 12-month

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: June 4, 2019
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. 18yrs=Age=75yrs .

2. De novo lesion at native coronary artery.

3. Single target vessel and single target lesion.

4. Lesion length =32mm.

5. RVD 2.5mm~4.0mm.

6. DS%=70% by visual estimation.

7. Target lesion could be covered by only one stent.

8. Subjects are willing to follow the specified requirements follow-up.

9. A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.

Exclusion Criteria:

1. AMI within one week.

2. CTO(TIMI0),LM lesion,ostial lesion,graft vessel lesion,bifurcation (side branch RVD=2.5mm),ISR,mutivessel disease need to be treated.

3. Severe calcified lesion unable to predilate.

4. extremely tortuous proximal to the lesion that is inadequate to stent delivery.

5. NYHA=? or LVEF=40%.

6. Prior stenting within 1 year.

7. Pregnancy or lactation, and plan in postoperative pregnancy or lactation.

8. Subjects had bleeding tendency or blood coagulation dysfunction or PCI contraindications, or anticoagulant therapy taboo or can't continue DAPT healers at least 1 year.

9. There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (< 1 year).

10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy.

11. Serious liver and kidney function is not complete person.

12. The investigators think that do not fit to enroll the study.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Ischemia

Intervention

Device:
• EXCEL-?
A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-? with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions

Locations

Country	Name	City	State
China	Shenyang Northern Hospital	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
JW Medical Systems Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary endpoint(MACE)	Device oriented cardiovascular endpoint at 30-day (MACE) defined as the composite of Cardiac Death,Myocardial Infarction(Q and non-Q) or Ischemia-driven Target Lesion Revascularization	30days(MACE)
Secondary	Secondary endpoint	In-stent Late Lumen Loss at 4-month and 12-month	5 years (Follow-up)